Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.32
AZN's Cash-to-Debt is ranked lower than
79% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. AZN: 0.32 )
Ranked among companies with meaningful Cash-to-Debt only.
AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 0.88 Max: 10.55
Current: 0.32
0.19
10.55
Equity-to-Asset 0.21
AZN's Equity-to-Asset is ranked lower than
93% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.43 Max: 0.59
Current: 0.21
0.21
0.59
Debt-to-Equity 1.45
AZN's Debt-to-Equity is ranked lower than
90% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. AZN: 1.45 )
Ranked among companies with meaningful Debt-to-Equity only.
AZN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.43 Max: 1.45
Current: 1.45
0.03
1.45
Debt-to-EBITDA 2.71
AZN's Debt-to-EBITDA is ranked lower than
65% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. AZN: 2.71 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AZN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09  Med: 1.11 Max: 2.71
Current: 2.71
0.09
2.71
Interest Coverage 6.88
AZN's Interest Coverage is ranked lower than
78% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. AZN: 6.88 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 4.19  Med: 8.2 Max: 19.13
Current: 6.88
4.19
19.13
Piotroski F-Score: 5
Altman Z-Score: 1.68
Beneish M-Score: -2.45
WACC vs ROIC
6.16%
18.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 24.96
AZN's Operating Margin % is ranked higher than
88% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. AZN: 24.96 )
Ranked among companies with meaningful Operating Margin % only.
AZN' s Operating Margin % Range Over the Past 10 Years
Min: 8.05  Med: 28.16 Max: 38.09
Current: 24.96
8.05
38.09
Net Margin % 17.83
AZN's Net Margin % is ranked higher than
83% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. AZN: 17.83 )
Ranked among companies with meaningful Net Margin % only.
AZN' s Net Margin % Range Over the Past 10 Years
Min: 4.64  Med: 19.12 Max: 29.72
Current: 17.83
4.64
29.72
ROE % 29.06
AZN's ROE % is ranked higher than
92% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. AZN: 29.06 )
Ranked among companies with meaningful ROE % only.
AZN' s ROE % Range Over the Past 10 Years
Min: 5.9  Med: 31.4 Max: 45.52
Current: 29.06
5.9
45.52
ROA % 6.27
AZN's ROA % is ranked higher than
63% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. AZN: 6.27 )
Ranked among companies with meaningful ROA % only.
AZN' s ROA % Range Over the Past 10 Years
Min: 2.2  Med: 12.84 Max: 18.34
Current: 6.27
2.2
18.34
ROC (Joel Greenblatt) % 70.86
AZN's ROC (Joel Greenblatt) % is ranked higher than
93% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. AZN: 70.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.37  Med: 119.25 Max: 199.64
Current: 70.86
30.37
199.64
3-Year Revenue Growth Rate 5.10
AZN's 3-Year Revenue Growth Rate is ranked lower than
51% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: 5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.9  Med: 2.5 Max: 19.9
Current: 5.1
-9.9
19.9
3-Year EBITDA Growth Rate 0.90
AZN's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. AZN: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 10.1 Max: 24.8
Current: 0.9
-30.1
24.8
3-Year EPS without NRI Growth Rate 21.10
AZN's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. AZN: 21.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AZN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 11.7 Max: 70
Current: 21.1
-48.9
70
GuruFocus has detected 8 Warning Signs with AstraZeneca PLC AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AZN Guru Trades in Q3 2016

Andreas Halvorsen 4,175,587 sh (New)
Ken Fisher 1,977,585 sh (+483.39%)
NWQ Managers 839,815 sh (+46.57%)
Dodge & Cox 42,189,973 sh (+29.68%)
PRIMECAP Management 17,313,325 sh (+12.67%)
Manning & Napier Advisors, Inc 495,960 sh (+1.68%)
Jeremy Grantham 594,800 sh (+1.29%)
David Dreman 1,321 sh (unchged)
Murray Stahl 28,302 sh (unchged)
Francis Chou 13,000 sh (unchged)
John Hussman 2,000 sh (unchged)
Pioneer Investments 446,742 sh (-0.11%)
Jim Simons 5,702,700 sh (-4.41%)
» More
Q4 2016

AZN Guru Trades in Q4 2016

Sarah Ketterer 514,612 sh (New)
Steven Cohen 676,000 sh (New)
Pioneer Investments 1,194,403 sh (+167.36%)
PRIMECAP Management 25,980,275 sh (+50.06%)
Dodge & Cox 49,613,588 sh (+17.60%)
NWQ Managers 945,170 sh (+12.55%)
Murray Stahl 28,302 sh (unchged)
Francis Chou 13,000 sh (unchged)
John Hussman 2,000 sh (unchged)
Manning & Napier Advisors, Inc 495,960 sh (unchged)
Ken Fisher 1,950,999 sh (-1.34%)
Andreas Halvorsen 2,859,129 sh (-31.53%)
Jeremy Grantham 240,631 sh (-59.54%)
Jim Simons 1,394,800 sh (-75.54%)
David Dreman 180 sh (-86.37%)
» More
Q1 2017

AZN Guru Trades in Q1 2017

Charles Brandes 236,779 sh (New)
Sarah Ketterer 735,062 sh (+42.84%)
PRIMECAP Management 34,310,950 sh (+32.07%)
Dodge & Cox 56,906,499 sh (+14.70%)
Murray Stahl 28,302 sh (unchged)
John Hussman 2,000 sh (unchged)
Steven Cohen 1,200,000 sh (unchged)
David Dreman Sold Out
Francis Chou Sold Out
Andreas Halvorsen Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments 1,185,803 sh (-0.72%)
Ken Fisher 1,921,092 sh (-1.53%)
NWQ Managers 710,935 sh (-24.78%)
» More
Q2 2017

AZN Guru Trades in Q2 2017

Jim Simons 130,700 sh (New)
Steven Cohen 603,108 sh (New)
David Dreman 180 sh (New)
Ken Fisher 11,081,856 sh (+476.85%)
PRIMECAP Management 37,900,350 sh (+10.46%)
Pioneer Investments 1,199,570 sh (+1.16%)
Murray Stahl 28,537 sh (+0.83%)
John Hussman 2,000 sh (unchged)
Dodge & Cox 56,669,449 sh (-0.42%)
Charles Brandes 231,588 sh (-2.19%)
NWQ Managers 495,175 sh (-30.35%)
Sarah Ketterer 414,856 sh (-43.56%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-06-30 Reduce -0.42%0.01%$29.76 - $35.36 $ 34.787%56,669,449
Ken Fisher 2017-06-30 Add 476.85%0.5%$29.76 - $35.36 $ 34.787%11,081,856
NWQ Managers 2017-06-30 Reduce -30.35%0.09%$29.76 - $35.36 $ 34.787%495,175
Charles Brandes 2017-06-30 Reduce -2.19%$29.76 - $35.36 $ 34.787%231,588
David Dreman 2017-06-30 New Buy$29.76 - $35.36 $ 34.787%180
Dodge & Cox 2017-03-31 Add 14.70%0.19%$26.72 - $31.8 $ 34.7819%56,906,499
Ken Fisher 2017-03-31 Reduce -1.53%$26.72 - $31.8 $ 34.7819%1,921,092
NWQ Managers 2017-03-31 Reduce -24.78%0.09%$26.72 - $31.8 $ 34.7819%710,935
Charles Brandes 2017-03-31 New Buy0.11%$26.72 - $31.8 $ 34.7819%236,779
David Dreman 2017-03-31 Sold Out $26.72 - $31.8 $ 34.7819%0
Dodge & Cox 2016-12-31 Add 17.60%0.18%$25.81 - $33 $ 34.7823%49,613,588
Ken Fisher 2016-12-31 Reduce -1.34%$25.81 - $33 $ 34.7823%1,950,999
NWQ Managers 2016-12-31 Add 12.55%0.04%$25.81 - $33 $ 34.7823%945,170
David Dreman 2016-12-31 Reduce -86.37%0.03%$25.81 - $33 $ 34.7823%180
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:LLY, LSE:GSK, NYSE:BMY, XTER:BAYN, XPAR:SAN, NYSE:ABBV, TSE:4503, TSE:4519, TSE:4578, TSE:4568, TSE:4528, HKSE:01093, MIL:REC, TSE:4151, BOM:500087, BOM:500302, TSE:4536, ISX:KLBF, SHSE:600436, XKRX:008930 » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, AZN.Switzerland, AZN.UK, AZNCF.USA,
Headquarter Location:UK
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing slightly less than 30% of its sales.

Guru Investment Theses on AstraZeneca PLC

Dodge & Cox Funds Comments on AstraZeneca - Aug 01, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatments for cancer, respiratory illnesses, cardiovascular problems, and infectious diseases. In the second half of 2016, the share price was under pressure due to concerns about recent and upcoming patent expirations for several of its major drugs. Despite this headwind, we added to the Fund’s holding in early 2017 after reaffirming our investment thesis.



The company’s long -term growth outlook is favorable given its robust new drug pipeline, particularly in oncology (cancer treatment). AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease-fighting capabilities of the body’s immune system to attack cancerous tumors. We have conducted extensive due diligence, which included industry conferences and management meetings, and we continue to believe the immuno-oncology (IO) field holds great promise. Since the IO market is in its very early stages, sponsors and the scientific community are



investing heavily into understanding which tumors can be targeted with IO and which patients will be most responsive to IO treatments (i.e., biomarkers). We think the field will evolve rapidly over the next five to ten years as physicians develop a better understanding of how these drugs work, creating a massive revenue and profit opportunity. With a 4.3% dividend yield, the current valuation is reasonable at 17 times forward earnings and does not appear to reflect potential success from the immunotherapy drug pipeline. AstraZeneca shares represented 1.9% of the Fund on June 30.



From Dodge & Cox Stock Funds second quarter 2017 shareholder letter.



Check out Dodge & Cox latest stock trades

Dodge & Cox Comments on AstraZeneca - Feb 06, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline.





From Dodge & Cox's Global Stock Fund 4th quarter 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about AstraZeneca PLC

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma
Dodge & Cox Funds Comments on AstraZeneca Guru stock highlight
AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatments for cancer, respiratory illnesses, cardiovascular problems, and infectious diseases. In the second half of 2016, the share price was under pressure due to concerns about recent and upcoming patent expirations for several of its major drugs. Despite this headwind, we added to the Fund’s holding in early 2017 after reaffirming our investment thesis. Read more...
Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
Causeway International Value Buys AstraZeneca, Gildan Fund invests in biopharmaceuticals, apparel in 4th quarter
Sarah Ketterer (Trades, Portfolio)’s Causeway International Value (Trades, Portfolio) added two holdings to its portfolio during the fourth quarter. They are AstraZeneca PLC (LSE:AZN) and Gildan Activewear Inc. (TSX:GIL). Read more...
Dodge & Cox Comments on AstraZeneca Guru stock highlight
AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline. Read more...
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China

Roxadustat: effective in dialysis (hemodialysis and peritoneal dialysis) and non-dialysis chronic kidney disease (CKD) patients

SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd. (FibroGen China), today reported positive topline results from the two Phase 3 clinical studies of roxadustat (FG-4592 or 罗沙司他[1]) designed to support new drug application submission in China.  Roxadustat is a first-in-class, orally administered small molecule for treatment of anemia in dialysis-dependent CKD (DD-CKD) and non-dialysis-dependent CKD (NDD-CKD) patients. Both of the Phase 3 studies met their primary efficacy endpoints, which were evaluated in the comparator-controlled portions of the studies. In the double-blind, placebo-controlled eight-week portion of the 26-week NDD-CKD trial, 151 anemia patients were randomized 2:1 to receive roxadustat (n=101) or placebo (n=50). Roxadustat met its primary efficacy endpoint of correcting anemia, by achieving a statistically significant increase in hemoglobin (Hb) levels compared to placebo over eight weeks. Furthermore, the secondary endpoint of Hb response was met as Hb response was achieved by a higher proportion of patients in the roxadustat arm than in the placebo arm. Roxadustat-treated patients achieved a mean Hb increase of 1.9g/dL from baseline (8.9g/dL) over eight weeks of treatment vs. a mean change in Hb of -0.4g/dL (from 8.9 g/dL baseline) in the placebo arm (p<0.00001).  A significantly higher proportion of roxadustat patients achieved Hb response (an increase ≥1g/dL from baseline) after eight weeks vs. placebo patients, 84.2% compared to 0.0% (p<0.00001). In the dialysis study, 304 patients (271 hemodialysis and 33 peritoneal dialysis patients) previously on epoetin alfa were randomized to and treated with roxadustat (n=204) or epoetin alfa (n=100) for 26 weeks. All the patients randomized to the active comparator arm were treated with 利血宝® (“Li Xue Bao”) epoetin alfa, manufactured in Japan and marketed in China by Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. (Kirin EPO). The primary endpoint was Hb change from baseline to the Hb level averaged during the final five weeks of the 26-week treatment period. Roxadustat met the predefined non-inferiority criterion for its primary endpoint in comparison to Kirin EPO in both full analysis set (FAS) and per protocol set (PPS) analyses.Furthermore, on superiority testing of the primary endpoint, the mean Hb increase observed in the roxadustat arm was higher than in the Kirin EPO arm, 0.75g/dL vs. 0.46g/dL (p=0.037) in PPS analysis. Initial findings suggest that adverse events were consistent with previous clinical trials of roxadustat in the CKD patient population with no new or unexpected safety signals identified. The 52-week safety assessment in at least 100 patients is ongoing with expected study completion in June 2017. Full results from these Phase 3 trials are expected to be reported in due course.  “We are grateful for the opportunity to advance development of treatment for anemia associated with CKD, a serious and potentially life-threating condition, for patients in China and worldwide,” said Tom Neff, Chief Executive Officer of FibroGen. “We are very encouraged by the topline results of these two pivotal Phase 3 studies for roxadustat, which bring us closer to the first oral anemia therapy that does not require injectable administration or IV iron supplementation. In addition, use of roxadustat is free of the burden of cold-chain storage and maintaining sterility, and costly distribution infrastructure. Data from these two studies will be used to complete our new drug application submission in China later this year.” FibroGen and AstraZeneca (NYSE:NYSE:AZN) are collaborating for the development and commercialization of roxadustat in China, the U.S., and other markets. In China, FibroGen is conducting all clinical trials and will hold all roxadustat regulatory licenses and permits to be issued by China regulatory authorities. After market approval, FibroGen China will manage manufacturing and medical affairs and AstraZeneca will manage launch and commercialization activities in China. About the FGCL-4592-808 and FGCL-4592-806 Studies FGCL-4592-808 Phase 3 Study in CKD patients not on dialysis in China: This is a double-blind, placebo-controlled multi-center study in 151 patients, randomized 2:1 to roxadustat or placebo for the first eight weeks, during which 101 patients received roxadustat (initial dose of 70 mg or 100 mg, based on body weight) and 50 patients received placebo three times weekly (TIW), followed by dose titration to Hb levels every four weeks as needed. After the initial eight-week period, placebo-treated patients are crossed over to receive 18 weeks of roxadustat treatment, while the active arm continues on roxadustat for the same period. Primary efficacy endpoint is Hb change from baseline at the end of Week 8.  A subset of roxadustat-treated patients entered the ongoing open-label extension for safety assessment and will receive roxadustat for up to 52 weeks of continuous exposure. FGCL-4592-806 Phase 3 Study in CKD patients on dialysis in China: This is a multi-center, randomized, epoetin alfa-controlled, open-label study in 304 patients over 26 weeks. CKD patients on chronic dialysis (whose anemia was previously treated with stable doses of one or more of nine brands of commercially available epoetin alfa) were randomized 2:1 to roxadustat or Kirin EPO, with 202 patients receiving roxadustat (initial dose of 100 mg or 120 mg TIW, based on body weight) and 100 patients receiving Kirin EPO, followed by dose titration to Hb levels every four weeks as needed. A subset of roxadustat-treated patients entered the ongoing open-label extension for safety assessment and will receive roxadustat for up to 52 weeks of continuous exposure. About CKD Anemia in China Anemia commonly develops in association with chronic kidney disease (CKD) and is linked to significant morbidity and mortality in both the dialysis and non-dialysis populations. CKD affects an estimated 119.5 million patients in China (Zhang et al. Lancet 2012; 379: 815–822). Although CKD may occur at any age, it is more common in aging populations, and its prevalence is increasing. CKD can be both a cause and a consequence of cardiovascular disease and is a critical healthcare issue. Currently, there is no treatment available that is curative or has the ability to stop kidney deterioration in patients with CKD with the exception of kidney transplantation.  The dialysis population in China, exceeding 400,000 patients, has been growing at a double-digit rate. The number of patients that require anemia therapy in China and other emerging markets is expected to increase steadily, as the CKD population continues to grow and the number of hemodialysis and peritoneal dialysis patients increases. We believe there is a significant opportunity for roxadustat to treat CKD anemia patients on dialysis (hemodialysis and peritoneal dialysis) and not on dialysis, as well as to address need in the large number of patients whose anemia remains undertreated or untreated in China. About Roxadustat  Roxadustat (FG-4592) is a first-in-class, orally administered small molecule currently in global Phase 3 clinical development as a potential therapy for anemia associated with CKD. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis – increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients – including in the presence of inflammation and without a need for supplemental intravenous iron.  Roxadustat is currently advancing through Phase 3 clinical trials worldwide, supported by extensive Phase 2 clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. To date, roxadustat has been evaluated in Phase 1 and Phase 2 studies, involving more than 1,400 subjects. Globally, a total of 15 Phase 3 studies, with target enrollment of about 10,000 patients worldwide, are currently being conducted to support independent regulatory approvals of roxadustat in both NDD-CKD and DD-CKD patients in the U.S., Europe, Japan, and China.  AstraZeneca and FibroGen are collaborating for the development and commercialization of roxadustat in the U.S., China, and other markets.  In China, FibroGen China is conducting all clinical trials and will hold all roxadustat regulatory licenses and permits to be issued by China regulatory authorities. After market approval, FibroGen China will manage manufacturing and medical affairs and AstraZeneca will manage launch and commercialization activities in China. Astellas and FibroGen are collaborating for the development and commercialization of roxadustat in Europe, Japan, the Commonwealth of Independent States, the Middle East, and Africa. Roxadustat is also entering a Phase 3 clinical trial in the U.S. for treatment of anemia in patients with myelodysplastic syndrome (MDS). In China, a roxadustat MDS Phase 2/3 clinical trial application (CTA) is currently under review by the China Food and Drug Administration (CFDA). For information about roxadustat studies currently recruiting patients, please visit clinicaltrials.gov at this link: https://clinicaltrials.gov/ct2/results?term=FG-4592&Search=Search About FibroGen

FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in CKD. Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne’s muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com. Forward-Looking Statements This release contains forward-looking statements, including statements regarding the potential ability of roxadustat to treat anemia in CKD patients, and the potential commercial market for roxadustat worldwide, including in China and emerging markets, timelines for study completion, reporting data, and clinical and regulatory developments for roxadustat. Our actual results may differ materially from these early data and any forward-looking statements due to risks and uncertainties that are described in our Annual Report on Form 10-K and our quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth therein.  Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. [1] China Approved Drug Name or China generic name for “roxadustat”
Contact

FibroGen, Inc.
Karen L. Bergman
VP, Investor Relations and Corporate Communications
1.415.978.1433
[email protected]

Read more...
SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors

— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — — SCYNEXIS to ramp up commercial preparatory and territorial licensing activities for its lead product, SCY-078 —
JERSEY CITY, N.J., Jan. 26, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced the appointment of Marion McCourt to its Board of Directors. Ms. McCourt most recently served as Chief Operating Officer of Medivation, Inc., a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options, until the acquisition of Medivation by Pfizer in September 2016. The appointment expands the SCYNEXIS Board to eight members.    "Marion brings diverse operational and commercial expertise to the SCYNEXIS Board as we prepare to advance our promising lead anti-fungal candidate, SCY-078, into later-stage trials and commence pre-commercial activities,” said Guy Macdonald, Chairman of the Board of SCYNEXIS. "On behalf of my fellow Board members, I would like to welcome Marion and look forward to her contributions and expertise as we carry out the important work of bringing novel antifungal treatments to patients." "2016 was a successful year for our company, and given our recent clinical progress with SCY-078, the addition of Marion’s commercial, marketing and reimbursement expertise to our Board will serve us well," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We are privileged to have Marion join us at this important time in our evolution, and we are eager to leverage her insights and guidance as we continue to advance the development of SCY-078 in multiple indications and to expand our business development activities." “It has been many years since significant advancements have been made in the fight against invasive fungal infections, and growing resistance to current treatment alternatives is quickly emerging as a global public health crisis,” said Ms. McCourt. “I am impressed by SCYNEXIS’ progress to date, and I believe that SCY-078 has the potential to address significant unmet medical needs. I am honored to join such an impressive team of executives and directors, and I look forward to contributing to the Company’s future success.”  Ms. McCourt brings to the SCYNEXIS Board more than two decades of wide-ranging leadership experience at several of the world's most respected and innovative biopharmaceutical companies. Prior to joining Medivation as Chief Operating Officer in February 2016, Ms. Marion served as Vice President of U.S. Commercial Operations at Amgen Inc. (NASDAQ:AMGN), one of the world's leading independent biotechnology companies. Prior to that, she also served as Vice President and General Manager of Amgen’s Bone Health & Primary Care Business Unit. Before joining Amgen, Ms. McCourt held numerous positions of increasing responsibility over a twelve-year career at AstraZeneca (NYSE:NYSE:AZN) in the U.S. and Canada. There, she ultimately achieved the title of Chief Operating Officer of AstraZeneca U.S. where she was responsible for all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, and corporate affairs. Ms. McCourt holds a B.S. degree in Biology from Lafayette College. About SCYNEXIS, Inc. SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com. Forward Looking Statement Statements contained in this press release regarding matters that are expected to occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to:  SCYNEXIS’s plan to  advance SCY-078 to the next stages of development in  2017. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS' ability to successfully develop SCY-078, including SCYNEXIS' ability to obtain FDA approval for SCY-078; the expected costs of studies and when they might begin or be concluded; and SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT:

Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781.235.3060
[email protected]

Investor Relations
Susan Kim
Argot Partners
Tel: 212.203.4433
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 21.46
AZN's PE Ratio is ranked higher than
64% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.41 vs. AZN: 21.46 )
Ranked among companies with meaningful PE Ratio only.
AZN' s PE Ratio Range Over the Past 10 Years
Min: 6.03  Med: 12.15 Max: 99.64
Current: 21.46
6.03
99.64
Forward PE Ratio 18.12
AZN's Forward PE Ratio is ranked higher than
54% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.53 vs. AZN: 18.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.46
AZN's PE Ratio without NRI is ranked higher than
65% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.56 vs. AZN: 21.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
AZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.03  Med: 12.15 Max: 99.64
Current: 21.46
6.03
99.64
Price-to-Owner-Earnings 20.26
AZN's Price-to-Owner-Earnings is ranked higher than
75% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.43 vs. AZN: 20.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.37  Med: 11.58 Max: 45.35
Current: 20.26
5.37
45.35
PB Ratio 6.14
AZN's PB Ratio is ranked lower than
79% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. AZN: 6.14 )
Ranked among companies with meaningful PB Ratio only.
AZN' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 3.77 Max: 6.93
Current: 6.14
2.3
6.93
PS Ratio 3.81
AZN's PS Ratio is ranked lower than
58% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. AZN: 3.81 )
Ranked among companies with meaningful PS Ratio only.
AZN' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.39 Max: 4.03
Current: 3.81
1.61
4.03
Price-to-Free-Cash-Flow 60.03
AZN's Price-to-Free-Cash-Flow is ranked lower than
80% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.72 vs. AZN: 60.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.18  Med: 14.19 Max: 179.65
Current: 60.03
6.18
179.65
Price-to-Operating-Cash-Flow 26.71
AZN's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. AZN: 26.71 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.35  Med: 8.6 Max: 33.31
Current: 26.71
5.35
33.31
EV-to-EBIT 20.69
AZN's EV-to-EBIT is ranked lower than
53% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. AZN: 20.69 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 8.5 Max: 61
Current: 20.69
4.2
61
EV-to-EBITDA 13.60
AZN's EV-to-EBITDA is ranked higher than
62% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. AZN: 13.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.8 Max: 20.6
Current: 13.6
3.6
20.6
EV-to-Revenue 4.50
AZN's EV-to-Revenue is ranked lower than
60% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. AZN: 4.50 )
Ranked among companies with meaningful EV-to-Revenue only.
AZN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2.5 Max: 4.7
Current: 4.5
1.6
4.7
Shiller PE Ratio 19.74
AZN's Shiller PE Ratio is ranked higher than
80% of the 204 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.18 vs. AZN: 19.74 )
Ranked among companies with meaningful Shiller PE Ratio only.
AZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10  Med: 13.79 Max: 20.61
Current: 19.74
10
20.61
Current Ratio 0.91
AZN's Current Ratio is ranked lower than
92% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. AZN: 0.91 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.46 Max: 2.03
Current: 0.91
0.64
2.03
Quick Ratio 0.73
AZN's Quick Ratio is ranked lower than
89% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. AZN: 0.73 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.23 Max: 2.03
Current: 0.73
0.54
2.03
Days Inventory 232.97
AZN's Days Inventory is ranked lower than
88% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. AZN: 232.97 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.03 Max: 232.97
Current: 232.97
88.45
232.97
Days Sales Outstanding 85.42
AZN's Days Sales Outstanding is ranked lower than
60% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. AZN: 85.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.99  Med: 71.38 Max: 95.12
Current: 85.42
40.99
95.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.03
AZN's Dividend Yield % is ranked higher than
92% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. AZN: 4.03 )
Ranked among companies with meaningful Dividend Yield % only.
AZN' s Dividend Yield % Range Over the Past 10 Years
Min: 2.67  Med: 4.61 Max: 6.88
Current: 4.03
2.67
6.88
Dividend Payout Ratio 0.92
AZN's Dividend Payout Ratio is ranked lower than
88% of the 416 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 0.92 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AZN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.37  Med: 0.53 Max: 2.89
Current: 0.92
0.37
2.89
3-Year Dividend Growth Rate 9.10
AZN's 3-Year Dividend Growth Rate is ranked higher than
56% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. AZN: 9.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AZN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -4.5  Med: 9.5 Max: 41
Current: 9.1
-4.5
41
Forward Dividend Yield % 2.59
AZN's Forward Dividend Yield % is ranked higher than
91% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. AZN: 2.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.92
AZN's 5-Year Yield-on-Cost % is ranked higher than
90% of the 849 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. AZN: 4.92 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AZN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.25  Med: 5.61 Max: 8.37
Current: 4.92
3.25
8.37
3-Year Average Share Buyback Ratio -0.20
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. AZN: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 1.1 Max: 4.9
Current: -0.2
-23.3
4.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.41
AZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
50% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. AZN: 2.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.4 Max: 8.67
Current: 2.41
0.48
8.67
Price-to-Median-PS-Value 1.60
AZN's Price-to-Median-PS-Value is ranked lower than
78% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. AZN: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.22 Max: 2.49
Current: 1.6
0.57
2.49
Earnings Yield (Greenblatt) % 4.85
AZN's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. AZN: 4.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.8 Max: 23.6
Current: 4.85
1.6
23.6
Forward Rate of Return (Yacktman) % -7.75
AZN's Forward Rate of Return (Yacktman) % is ranked lower than
83% of the 397 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.07 vs. AZN: -7.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AZN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.7  Med: 18.5 Max: 27.6
Current: -7.75
-17.7
27.6

More Statistics

Revenue (TTM) (Mil) $21,740.00
EPS (TTM) $ 1.53
Beta0.65
Short Percentage of Float0.00%
52-Week Range $25.55 - 35.60
Shares Outstanding (Mil)2,532.00 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 21,929 22,316 25,243
EPS ($) 1.78 1.79 2.40
EPS without NRI ($) 1.78 1.79 2.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.71%
Dividends per Share ($) 1.41 1.44 1.47

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}